



AN INVESTIGATIONAL SCREENING TEST

Cancer screening is an effective way to detect cancer early, when it can most easily be treated. Unfortunately, many people today are not being screened in line with recommendations.

Guardant Health is addressing this shortcoming by developing LUNAR-2, a blood test that seeks to increase screening rates and overcome the challenges of current methods, all from a simple blood draw.

To accomplish these objectives, Guardant Health is leveraging data from the tens of thousands of cancer patients it has already tested, as well as collaborating with multiple investigators at cancer centers around the world.

We at Guardant Health believe a simple blood test can improve lung cancer screening by overcoming barriers associated with current methods, such as low-dose CT scans, while still being effective and more accessible.

Ask your clinician today for more information on the Guardant LUNAR-2 test and the SHIELD study.



OUR COMPANY

Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics.



A STUDY FOR THE GUARDANT LUNAR-2 TEST

Inclusion Criteria

- Have an increased risk of lung cancer, incl. having at least a 20-pack/year smoking history and currently smoke or have quit within the past 15 years
- Be between 50 and 80 years old
- Are undergoing or intend to undergo a low-dose CT scan of the chest for lung cancer screening
- Are willing to consent to the investigational blood draw during index low-dose CT scan screening visit and before any invasive procedures or treatment for lung cancer diagnosis
- Are willing to consent to a 1-year, 2-year, and additional follow-up per protocol
- Additional criteria may apply



Exclusion Criteria

- Have smoked for less than 15 years or have less than a 20-pack/year smoking history
- Have a health problem that substantially limits life expectancy and/or the ability or willingness to have curative lung surgery
- Are undergoing low-dose CT chest scan for investigation of symptoms suspicious for lung cancer
- Have preexisting or a history of lung cancer, have a previously diagnosed high-risk lung lesion, or have a history of malignancy
- Are currently taking any anti-neoplastic or disease-modifying anti-rheumatic drugs
- Are currently receiving treatment for pneumonia
- Have had any major physical trauma within the 30 days leading up to informed consent
- Additional criteria may apply